Skip navigation

Pharma's Market

SPECIAL REPORT


Current DateTime: 06:39:35 21 Nov 2009
LinksList Documentid: 32984624

PHARMA'S MARKET VIDEO

» More

Current DateTime: 06:39:35 21 Nov 2009
LinksList Documentid: 31171988
Expiration DateTime: 11/21/2009 6:42:08 AM

RSS FEED

» Help

Current DateTime: 06:39:35 21 Nov 2009
LinksList Documentid: 31171995
powered by digg
Merck: Both Sides Now
Published: Friday, 13 Nov 2009 | 11:55 AM ET
Text Size
By: Mike Huckman
CNBC Correspondent

It doesn't always happen, but there is a common to-and-fro, push-and-pull, back-and-forth or whatever you want to call it between reporters and corporate PR folks. I don't particularly like that part of my job, but sometimes it just comes with the territory. I've got my job to do and they've got theirs. I get it.

However, earlier this week a Merck PR guy asked me, "Why are you making this such a big deal? It's a 200-patient study." When I tweeted it, one of my journalism pals on Twitter replied that they'd (I'm shielding their identity and gender) been told even worse on several occasions by various corp comm pitbulls: "Don't embarrass yourself," they reportedly said in a desperate last-ditch attempt to get a story spiked. I think if anyone ever said that to me I'd blow a gasket.

The Merck [MRK  Loading...      ()   ] rep was referring to our coverage plans for the Arbiter 6 clinical trial results that are coming out next Monday morning at 8 a.m. ET at the American Heart Association meeting and, according to analysts, simultaneously in "The New England Journal of Medicine."

I'll be reporting live from the event in Orlando on "Squawk Box" starting at 7:30 a.m. with a curtain-raiser and then with the breaking news at the top of the next hour.

I wonder if "New York Times" reporter Natasha Singer got the same treatment from Merck as I did. She wrote a big takeout on the test that pitted MRK's Zetia/Vytorin against Abbott's Niaspan [ABT  Loading...      ()   ]. In the print edition the story appears on the front page of the business section under the headline, "Cholesterol Study Rivets An Industry."

That apparently prompted "The Wall Street Journal Health Blog" to do kind of a counterpoint piece titled, "The Next Vytorin Study: Why Is Everybody So Worked Up?" I know Merck has to love that.

One analyst, Leerink Swann's Seamus Fernandez, says much of the reaction to the study will be dictated by the tone of two editorials he says will appear in NEJM alongside the results. But JPMorgan's Chris Schott says in a research note to clients this week, "The key swing factor when considering the potential impact to the (Vytorin/Zetia) cholesterol franchise will be the degree of media focus around the study."

We reporters get it from all sides.

Questions?  Comments?  and follow me on Twitter at mhuckman

© 2009 CNBC, Inc. All Rights Reserved
Add This share icon
Text Size
  • digg share
ADD COMMENTS
Remaining characters


Current DateTime: 01:02:04 21 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 01:02:04 21 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 01:02:04 21 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:02:05 21 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters